Jeffery S. Thompson

Mr. Thompson joined the Board of Directors of Anika Therapeutics in January 2011. He is a Partner with HealthEdge Investment Partners, LLC or HealthEdge, a Tampa, Florida based private equity firm that provides strategic capital exclusively to the healthcare industry. Mr. Thompson previously served as President, CEO, and Chairman of Advanced Bio-Technologies, Inc. and Enaltus, LLC, both HealthEdge portfolio companies specializing in unique skincare solutions. Mr. Thompson currently serves as a director or manager for various HealthEdge affiliated companies including, Legacy Xspire Holdings, Lifesync, Spectrum Medical Partners, and Westone. Prior to joining Anika, Mr. Thompson also served as the Chief Operating Officer and as a director for Stiefel Laboratories, Inc., an independent global pharmaceutical company specializing in dermatology, and President of Glades Pharmaceuticals, both of which were sold to GlaxoSmithKline in 2008. Earlier in his career, Mr. Thompson held sales and business management positions at Bausch & Lomb Pharmaceuticals and SmithKline Beecham. Mr. Thompson holds a B.S. in general science from the University of Pittsburgh. Mr. Thompson’s qualifications for membership on the Board include his prior experience in running a pharmaceutical company and his knowledge of the medical device industry, both of which provide the Board with product and business development perspectives and insights.